Azole resistance in Aspergillus terreus isolates was explored. Twenty related (MB) and 6 unrelated A. terreus isolates were included. CYP51A sequencing and RAPD genotyping was performed. Five MB isolates were itraconazole susceptible, whereas the minimum inhibitory concentrations (MICs) for 15 MB isolates were elevated (1-2 mg/L). Voriconazole and posaconazole MICs were 0.5-4 and 0.06-0.5 mg/L, respectively, for MB isolates but 0.25-0.5 and <0.03-0.06 mg/L, respectively, for controls. Sequencing identified a Cyp51Ap M217I alteration in all 15 isolates with elevated itraconazole MICs. Genotyping showed that 18 of 20 MB isolates were identical and unique, suggesting endogenous origin. In conclusion, itraconazole resistance in A. terreus was linked to an M217I Cyp51A alteration.
Itraconazole is often used for the treatment of chronic noninvasive forms of aspergillosis and has proven to be effective and steroid sparing in ABPA. Resistance to itraconazole in A. fumigatus is well recognized and was first reported in 1997 in 3 clinical isolates obtained during the late 1980s [2] . The main mechanism of azole resistance currently reported is alterations to the drug target encoded by the cyp51A gene but also others, and yet uncharacterized mechanisms are involved [1, [3] [4] [5] . Azole resistance in A. fumigatus has been reported in azole-exposed patients [3] but also in azole-naive patients and in the environment in the Netherlands [6] and Denmark [7] and linked to the use of azoles for agricultural and material preservation purposes. Acquired azole resistance in A. terreus would be particularly challenging, because this species is intrinsically resistant to amphotericin B. Over the past decade, a number of studies have investigated azole susceptibility in A. terreus without finding isolates with elevated itraconazole among >500 isolates. However, clearly elevated itraconazole minimal inhibitory concentrations (MICs) were found in 2 of 50 A. terreus isolates from Spain, 1 of 23 isolates in a recent study from the United States, and in isolates from 1 of 9 Danish patients with CF who were colonized with this species, suggesting acquired resistance in these particular isolates [1, 8, 9] . The underlying mechanism was, however, not investigated in any of these studies. Thus, in this study, we investigated the underlying resistance mechanism and origin in A. terreus isolates with reduced azole susceptibility from a Danish patient with CF (detailed case report provided as supplemental material).
MATERIALS AND METHODS

Isolates
Twenty sequential A. terreus isolates cultured from airway specimens from a Danish patient with CF (MB) obtained from November 2003 through March 2011 were included. The isolates were stored in glycerol broth until use. Six unrelated A. terreus isolates were included as controls; 2 of these were received in 1997 and 1999 as part of a quality assessment scheme from United Kingdom National External Quality Assessment Service (http://www.ukneqas.org.uk/content/page server.asp), whereas 4 were received as routine specimens from 4 unrelated patients without CF who were hospitalized at 4 different hospitals (Odense University Hospital, Esbjerg Sygehus, Århus University Hospital, and Copenhagen University Hospital Rigshospitalet) from 2004 through 2008.
Susceptibility Testing
Isolates were susceptibility tested according to EUCAST method using a single batch of susceptibility plates and evaluated blinded to the origin and characteristics of the isolates to avoid day-to-day or batch-to-batch variation and potential bias [10] . Manufacturers and stock solutions (5000 mg/L in dimethyl sulphoxide [Sigma-Aldrich, Brøndby]) were as follows: itraconazole (Sigma-Aldrich), voriconazole (Pfizer), posaconazole (Schering-Plough), and amphotericin B (SigmaAldrich). Final drug concentration ranges were 4-0.03 mg/L for the azoles and 8-0.03 mg/L for amphotericin B. MICs were determined visually as a no-growth end point at 48 h incubation time. Quality control strains Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were included but read after 24 hours of incubation (www.eucast.org). In addition, isolates were tested for susceptibility to amphotericin B using E-test strips (AB Biodisk) on RPMI-1640-2% glucose agar (#R-7755; Bacto Difco).
The following epidemiological cutoff values were used for A. terreus and azoles defining susceptibility, based on EUCAST wild-type distributions compiled from several European reference centers (www.eucast.org): itraconazole, ≤0.5; voriconazole, ≤2; and posaconazole, ≤0.25 mg/L.
Molecular Detection of Resistance Mechanisms
The full coding region (1542 bp) including promoter of the CYP51A gene was amplified by PCR (2311 bp in total) using primers designed in-house based on the sequence of reference strain NIH2624 ATEG05917 (Table 1) . Sequencing was performed by Macrogen, and the obtained 9 partial sequences for each isolate were assembled to the reference sequence using CLC DNA Workbench (CLC Bio). The generated CYP51A consensus sequences were subsequently translated and aligned for amino acid sequence analysis.
Molecular Genotyping
A. terreus isolates were taken from stock cultures and subcultured on sabouraud agar. DNA was extracted using the UltraClean microbial DNA Isolation Kit (Mo Bio Laboratories) according to the manufacturer's instructions. RAPD PCR was performed with 5 different primers to obtain maximal discriminatory power for A. terreus (Table 1) [11] . A 5-µL template containing 50 ng of A. terreus chromosomal DNA, 2.5 µL of 1 primer (20 pmol), and 17.5 µL of water were mixed with ReadyTo-Go RAPD analysis beads (Amersham Pharmacia Biotech) containing PCR buffer (30 mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, 2.5 µg of bovine serum albumin, 3 mmol/L MgCl 2 , 0.4 mmol/L dNTPs) and 1 unit of Amplitaq DNA polymerase. Thermocycling was done in a PCR cycler (UNO II; Bometra). The PCR products were analyzed by electrophoresis in a 1.8% agarose gel (6 hours at 80 V at room temperature) in 0.5 mmol/L Tris-borate-EDTA running buffer. The gels were photographed under UV light and analyzed. Highly related strains (groups) were defined as those having at least 90% homology on the basis of banding patterns. All experiments were performed in duplicate to assess reproducibility.
RESULTS
Susceptibility and Molecular Characteristics
With use of the epidemiological cutoff values (www.eucast. org) as susceptibility break points, overall, 19 of 20 MB isolates were classified as nonsusceptible to at least 1 azole, in contrast to none of the control isolates (Table 2) . For a single isolate (MB-09-2), azole MICs were low (itraconazole MIC 0.25 mg/L, posaconazole 0.06 mg/L, voriconazole 0.5 mg/L) and, thus, similar to the control isolates. Sequencing of the CYP51A target gene for azoles demonstrated no alterations in the 5 isolates that were classified as itraconazole susceptible. In contrast, a G651T mutation in the coding region of CYP51A was found in all other MB isolates leading to a methionine to isoleucine substitution at amino acid position M217 (M217I, Table 2 ). This mutation was not found in any of the control isolates, but one control isolate with wild-type susceptibility profile harbored an A221V alteration (RH) ( Table 2) .
To examine possible relatedness, RAPD-DNA genotyping was performed for all isolates. Eighteen of 20 MB isolates shared the same genotype, including 4/5 CYP51A wild-type and 14 of 15 isolates harboring the M217I substitution ( Table 2 , see Supplementary figure 2). The RAPD profile differed for 1 primer for 1 MB isolate (MB-09-5, A.terr-2, genotype B) and for 2 primers for another MB isolate (MB-09-2, A.terr-2 and NS7, genotype F) ( Table 2 ). The control isolates were all different from the MB isolates and, with one exception, also from one another. However, 2 isolates obtained as part of the quality control assessment scheme in 1997 and 1999 shared the same unique genotype, suggesting that the same isolate was used for both exercises and confirming the discriminatory power and robustness of the typing methodology (Table 2) .
We finally compared the azole and amphotericin B ranges for the following 3 groups of isolates: (1) the control isolates, (2) the genotype A wild-type MB isolates, and (3) the genotype A M217I MB isolates to better understand a potential role of the M217I alteration in reduced susceptibility (see Supplementary Table 3 ). Itraconazole, posaconazole, and voriconazole MIC ranges for the control isolates were lower and without any overlap to those of the 2 groups of MB isolates. Comparing the MB isolates with and without the M217I alteration, differential MIC levels were observed for itraconazole but not for posaconazole and voriconazole. No difference was seen comparing the amphotericin B MICs for the 3 groups of isolates, independently of which susceptibility testing method was applied in agreement with the CYP51A gene not being involved in amphotericin B susceptibility. 
DISCUSSION
The present findings demonstrate that acquired azole resistance is a clinical challenge that is not restricted to A. fumigatus. The sequencing results suggest a potential role of the M217I alteration in itraconazole resistance in A. terreus. This codon corresponds to M220 in A. fumigatus, because 3 amino acids found in the A. fumigatus Cyp51A protein (ie, at position 2, 31 and 32) are absent in A. terreus. In A. fumigatus, 5 different amino acid substitutions at codon M220 have been described, namely isoleucine, lysine, arginine, valine, and threonine, and all 5 alterations have been associated with itraconazole and posaconazole resistance; however, the voriconazole MICs vary [4] . However, the magnitude of the MIC increase depends on the specific amino acid alteration. Therefore, a potential role for codon M217 in azole resistance in A. terreus, as our data strongly suggest, would be in agreement with previous observations for A. fumigatus. Comparison of the MIC ranges of MB isolates of identical genotype and with and without this alteration revealed that only the itraconazole MIC was affected, suggesting that the alteration specifically leads resistance to this compound only and not multi-azole resistance as described above for A. fumigatus. Furthermore, the fact that this mutation was absent over the first 5 years of colonization but then persistently present since 2007 and that the wild-type and mutant isolates shared the same genotype strongly suggests endogenous origin caused by antifungal selection in vivo as is also well described in A. fumigatus [1] . Previously, it was shown that patients with CF may harbor single unique or several genotypes of A. fumigatus in their lungs, both at the same time and in serial samples [1] . Here, we show that the same is true for A. terreus. Thus, the vast majority of the sequential isolates shared the same genotype. For one isolate, the RAPD profile varied for one of the primers. This isolate shared the susceptibility profile of the other 13 genotype A isolates with elevated itraconazole MIC and had the same CYP51A mutation leading to the M217I substitution. We interpret this as microevolution occurring in the patient similar to what have been described for A. fumigatus isolates using STRAf typing in this patient population [1] . However, for another isolate, the RAPD profile varied for 2 of the primers. This isolate was without CYP51A mutations and, of interest, shared susceptibility profile with the unrelated control isolates, because posaconazole and voriconazole MICs were clearly below the epidemiological cutoff values. Therefore, we interpret this as an example of de novo inhalation of an unrelated isolate.
Another interesting finding was that moderately elevated azole MICs were also found in isolates without mutations in the target gene or promoter region, suggesting that another resistance mechanism was involved and introduced earlier than the M217I alteration. In the Manchester cohort of patients with chronic aspergillosis, half the patients during 2008-2009 with azole-resistant A. fumigatus harbored isolates with no CYP51A mutations [12] . Possible mechanisms in such isolates are over-expression of the target gene, which has been reported in isolates from a patient with underlying chronic granulomatous disease and long-term azole exposure [13] or the presence of efflux pumps, which has recently been shown using UV irradiation selected mutants and in in vitro and in vivo biofilm models using clinical isolates of A. fumigatus [14, 15] . In yeasts and A. fumigatus, several mechanisms often play in concert, as must have been the case in the resistant A. terreus isolates in our patient [5] .
In conclusion, the emergence of azole resistance in the A. terreus isolates in patients with CF is of particular concern. Firstly, patients may later develop Aspergillus bronchitis or severe complications, such as ABPA. Second, in patients undergoing lung transplantation, an azole-resistant invasive infection may develop. Third, this species is intrinsically a poor target for amphotericin B, leaving very few treatment options for infections involving isolates with acquired azole resistance.
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